Fujirebio Inc

At the onset of the twenty-first century, hospitals and medical care facilities worldwide still long for breakthroughs in clinical diagnostics for the early detection of serious diseases as well as in the development of therapeutic drugs. Under its management philosophy of Contributing to global healthcare through the creation of new values with respect for human life and commitment to people's health, Fujirebio, Inc. aims to be a global life science company focused on bioscience. Towards this end, Fujirebio implements various management strategies to be the unbeatable player in the Japanese clinical diagnostic field and foster the development of its oversea markets.

On July 1, 2005, Fujirebio made a new start under the holding company, Miraca Holdings Inc. As a member of Miraca Group, we all are determined to strive together for higher operating performance and further expansion of its businesses at an accelerated pace. To contribute to social affluence/health and global medical treatment, Fujirebio continues to work in the development of value-added original products, introduce new diagnostic test analytes, and strive to establish core technologies of the next generation. In the years to come, Fujirebio hopes to further enhance its presence as a key global life science company.

Automated Analyzer Systems
LUMIPULSE® Series
LUMIPULSE® G1200
LUMIPULSE® G600II

Immunological Fecal Occult Blood Test System
MagStream HT

SERODIA® Series
PA Series (PA: Particle agglutination)
HA Series (HA: Hemagglutination)

Other Series
Espline® Series (Immunochromatography)
Other Tests